# The therapeutic use of prostaglandins.

## Abstract
The use of a PGE like prostaglandin for the manufacture of a medicament for the treatment or prevention of a human suffering from or prone to acute respiratory distress syndrome or multiple vital organ damage, and for the treatment of a human suffering from shock, trauma, sepsis or any combination thereof.

## Claims
CLAIMS l. The use of a PGE like prostaglandin for the manufacture of a medicament for the treatment of a human suffering from acute respiratory distress syndrome or multiple vital organ damage. 2. The use of a PGE like prostaglandin for the manufacture of a medicament for the prevention of acute respiratory distress syndrome or multiple vital organ damage in a human prone to the syndrome or organ damage. 3. The use of a PGE like prostaglandin for the manufacture of a medicament for the treatment of a human suffering from shock, trauma, sepsis or any combination thereof. 4. The use of a PGE like prostaglandin for the manufacture of a medicament for reducing the probability of a fatal outcome for a human suffering from or prone to shock, trauma, sepsis or any combination thereof. 5. A use according to claim 1, for the prevention of multiple vital organ damage. 6. A use according to any preceding claim, wherein the medicament is suitable for administration for at least 7 days. 7. A use according to any preceding claim, wherein the prostaglandin has the formulaEMI24.1 wherein Nl is 1 COOR1, wherein R1 is a hydrogen, b C1 C12 alkyl, c Cl ClO cycloalkyl, d C6 C16 aralkyl, e phenyl, optionally substituted by one, 2 or 3 substituents independently selected from chloro and C1 C3 alkyl, f phenyl substituted in the para position by i WH CO R25, ii CO R26, iii O CO R54 or iv CH N NR CO NH2, wherein R25 is methyl, phenyl, acetamidophenyl, benzamidophenyl or NH2 R26 is methyl, phenyl, NH2 or methoxy and R54 is phenyl or acetamidophenyl or g a pharmacologically acceptable cation 2 CH2OH, 3 COL4, wherein L4 is a amino of the formula NR51R52 wherein R52 is i hydrogen or ii C1 C12 alkyl, and R51 is i hydrogen, ii C1 C12 alkyl, iii C3 C10 cycloalkyl, iv C7 Cl2 aralkyl, v phenyl optionally substituted by one, 2 or 3 substituents independently selected from chloro, C1 C3 alkyl, hydroxy, carboxy, C2 C5 alkoxycarbonyl and nitro, vi C2 C5 carboxyalkyl, vii C2 C5 carbamoylalkyl, viii C2 C5 cyanoalkyl, ix C3 C6 acetylalkyl, x C7 C11 benzoalkyl optionally substituted by one, 2 or 3 substituents independently selected from chloro, C1 C3 alkyl, hydroxy, C1 C3 alkoxy, carboxy, C2 C5 alkoxycarbonyl and nitro, xi pyridyl optionally substituted by one, 2 or 3 substituents independently selected from chloro, C1 C3 alkyl and C1 C3 alkoxy, xii C6 C9 pyridylalkyl optionally substituted by one, 2 or 3 substituents independently selected from chloro and C1 C3 alkyl, xiii C1 C4 hydroxyalkyl, xiv C2 C4 dihydroxyalkyl or xv C3 C4 trihydroxyalkyl, b cycloamino selected from pyrrolidino, piperidino, morpholino, piperazino, hexamethyleneimino, pyrrolino and 3,4 didehydropiperidinyl optionally substituted by one or 2 C1 C12 alkyl groups, c carbonylamino of the formula NR53COR 51, wherein R53 is H or Cl C4 alkyl and R is as defined for R51 but is not hydrogen, d sulfonylamino of the formula NR53SO2R51 , wherein R5,1 and R53 are as defined above, e CH2NL2L3, wherein L2 and L3 are independ ently selected from H and Cl C4 alkyl, f CO2R1, g CH2OR, h CONR5R6, wherein R5 and R6 are independently selected from H, CH3 and C2H5, i CH2 NR5R6, or j CONHSO2CH3 wherein M1 is cis or trans CH CH CH2 , CH2 n , CH2 n 1 CF2 , CO CH2 3 CH2 , trans CH2 m CH CH , CH CH CH2 m 1 CF2 or CO CH2 3 CF2 , m being 3, 4 or 5 and n being 5, 6 or 7 wherein L1 is alpha OH ss H, CH2 or oxo wherein R8 is hydrogen, hydroxy or methyl wherein E1 is trans CH CH, CH2CH2 or CEC wherein Q1 is alpha OH ss H, alpha OH ss CH3, alpha H ss OH, alpha CH3 ss OH or oxo wherein A, is alpha H ss CH3, alpha CH3 ss H, alpha H ss H, alpha F ss F or alpha CH3 ss CH3 and wherein R7 is 1 CH2 p CH3, p being from 1 to 6, 2 cis CH CH CH2 CH3, 3 CH2 2 C CH, 4 CH2 3 CH C CH3 2 or 5 C R3R4 CH2 g CH2R14, g being from 1 to 4, R3 and R4 being independently selected from H and CH3, and R14 being H or C1 C4 alkyl or a pharmacologically acceptable salt thereof. 8. A use according to any of claims 1 to 6, wherein the prostaglandin is selected from PGE1, 2 decarboxy 2 hydroxymethyl PGE1 15S 15 methyl PGE1 15R 15 methyl PGE1 16,16 dimethyl PGE1 PGE2 15 keto PGE2 16, 16 dimethyl PGE2 17S,20 dimethyl 6 oxo PGEl, methyl ester 17S,20 dimethyl trans delta 2 PGE1 PGE2, N methanesulfonylamide 9 deoxo 9 methylene 16,16 dimethyl PGE2 15S 15 methyl PGE2 1 SR 15 methyl PGE2 ll deoxy 16,16 dimethyl PGE2 11 deoxy 11 alpha , 16,16 trimethyl PGE2 6 oxo 11 deoxy 11 alpha ,16,16 trimethyl PGE2 6 oxo PGE2 6 oxo PGE1 11 deoxy 15 methyl PGE1 PGE3 16,16 difluoro PGE2 and 20 isopropylidene PGEl. 9. A use according to claim 8, wherein the prostaglandin is PGE1. 10. A use according to any of claims 1 to 6, wherein the prostaglandin is PGE2 or PGI2, or a salt, ester, amide or stabilised form or derivative thereof.

## Description
THE THERAPEUTIC USE OF PROSTAGLANDINS The present invention provides a new use of known pharmacological agents. In particular, this invention relates to method for treating patients with acute respiratory distress syndrome ARDS sometimes known as adult respiratory distress syndrome resulting from shock, trauma or sepsis and preventing death resulting from multiple organ damage in this disease. ARDS seems to be secondary to embolization to the lungs of microaggregates of platelets and or white cells.The syndrome, and the associated multiple organ failure, accounts for most of the noncerebral deaths of patients who have been resuscitated from shock, trauma, and sepsis or the other inciting events of TableI. The pulmonary failure is characterized by ventilation perfusion mismatching with low arterial oxygen concentrations, poor lung compliance, and in some cases, increased pulmonary vascular resistance. In addition to damage to the lungs, damage to other organs is associated with shock, trauma, and sepsis. Overall mortality in patients with ARDS or other severe organ failure, after shock, trauma, or sepsis, is over 50 . Current treatment of ARDS concentrates on treatment of the underlying shock, trauma, or sepsis. .Rapid resuscitation from shock, rapid control of bleeding, early institution of mechanical ventilation with a volume ventilator, and titration of intravascular volume, sometimes using a Swan Ganz pulmonary arterial catheter, help in treatment of shock.Immobilization of fractures, debridement of dead or devitalized tissue, drainage of pus, closure of holes in the gastrointestinal tract, diversion of the gastrointestinal tract proximal to damage, and administration of antibiotics can all help prevent the adverse effects of tissue trauma or infection. Only a few specific treatments, however, are available to treat ARDS or other organ failure once it develops.In those cases where patients are suffering from severe cases of ARDS, large doses of heparin therapy may be given in an attempt to reduce intravascular clotting and microembolization to the lungs. Heparin, however, increases the risk of additional bleeding in patients suffering from severe injuries. The method proposed here would treat ARDS and other organ failure after shock, trauma,or sepsis without risks of this sort. This invention also relates to a method for treating patients who are at risk for developing failure of vital organs lungs, liver, kidney, gastrointestinal tract, brain, or heart as a result of a catastrophic, traumatic, or septic event. These inciting catastrophic events have been extensively described for ARDS and some are listed in Table I. These are the events which place the patients treated by this invention at risk for vital organ failure. Like ARDS, failure of other vital organs may be secondary to the embolization and or deposition of platelets and or white blood cells to or in the liver, kidney, gastrointestinal tract, brain, or heart. Liver and kidney failure are usually noted initially by the appearance of pathologic levels of certain cell products in the blood bilirubin and creatinine, for example . Failure of the gastrointestinal tract may present with gastrointestinal bleeding. Brain dysfunction may present with disorientation. Heart dysfunction may present with congestive heart failure associated with low cardiac outputs and high end diastolic ventricular filling pressures. Bilirubin levels above 5 mg and creatinine levels above 2 mg S indicate failure of the liver or kidney.Gastrointestinal hemorrhage requiring transfusion represents failure of the gastrointestinal tract. Severe disorientation to person, time, or place represent brain dysfunction. A cardiac index less than 3.3 liters.min 0.m 2 associated with right atrial pressures greater than 8 mm Hg or left atrial pressures greater than 15 mm Hg represent failure of the heart these pressures are measured with respect to atmosphere with the pressure transducer located at the level of the mid thorax with the pressures being measured at end expiration . The patient population to be treated by the prostaglandins of this invention include those who have evidence of organ failure, diagnosed as previously described respiratory distress, embolization and or deposition of platelets or white cells to the vital organs, high levels of blood bilirubin or creatinine, gastrointestinal hemorrhage, disorientation, decreased cardiac index, etc. as a result of the inciting events such as those listed on Table 1 or who are at significant risk for organ failure as a result of the acute inciting events such as those of Table 1.These risks are generally known to those skilled in the art and include the following 1 Any septic or traumatic insult that results in the patient requiring ventilatory support This is evidence of beginning lung failure. 2 Documented peritonitis 3 Lung contusion or major thoracic trauma tri Major non thoracic trauma 5 An operative procedure requiring 6 or more units of blood in the perioperative period 6 Second or third degree burns involving about 30 or more of the patient s body 7 Significant fat embolization resulting from trauma or surgery 8 Hemorrhagic or septic shock 9 Cardiogenic or anaphylactic shock 10 Severe viral, bacterial or fungal pneumonia 11 Inhalation of oxygen greater than 50S 02 , smoke or nitrous oxide for an extended period of time 12 Aspiration of gastric contents into the lungs 13 Drug overdose 111 Disseminated intravascular coagulation 15 Near drowning fresh or salt water 16 Pancreatitis or uremia 17 Patients requiring long periods on cardiopulmonary bypass 18 Patients whose heart has stopped for a prolonged period greater than 3 minutes 19 Air or amniotic fluid embolization and 20 Any patient who requires multiple transfusions of 6 or more units of blood. See, also, e.g., Pepe, et al., Clinical Predictors or the AdultRespiratory Distress Syndrome, American Journal of Surgery, 144 124 1982 . The prostaglandins used in the present invention are derivatives of prostanoic acid. A trivial system of nomenclature has been devised, which classifies the prostaglandins according to the substituents on the cyclopentane ring. See, N.A. Nelson, Journal of MedicinalChemistry, 17 911 1974 . For a further discussion of the prostaglandins, see Bergstrom, et al., Pharmacol. Rev. 20 1 1968 , and references cited therein. The term prostaglandin analog herein refers to those compounds structurally related to the prostaglandins in that they exhibit a cyclopentane, or adjacently homologous cycloalkane, ring and a pair of side chains attached to adjacent carbon atoms of the ring which retain characteristic biological properties of the prostaglandins.See Bergstrom, cited above. Various structural modifications of the prostaglandins are known to produce useful prostaglandin analogs.Many of these structural modifications are discussed in the U.S. patents set forth below. Prostaglandin E1 PGE1 , PGE2 and PGI2 are known derivatives of prostanoic acid. P 1, its lower alkyl esters, salts and amides are known to be potent pharmaceutical agents. The use of PGE1 and its alkyl esters, salts and amides for the treatment of peripheral vascular disease by non intrarterial administration is described in U.S. Patent 11,103,026.In U.S. Patent 4,116,988 various uses of P 1 are described. They include stimulation of smooth muscles antilipolytic activity stimulation of epidermal proliferation and keratinization treatment of nasal congestion treatment of bronchial asthma bronchitis bronchiectasis pneumonia and emphysema use as additives to blood, blood products, blood substitutes and other fluids which are used in artificial extracorporeal circulation and perfusion of isolated body parts and induction of labor in female animals. PGI2, also known as prostacyclin, and its pharmaceutically acceptable salts, esters and amides have exhibited potent pharmacological activity. See U.S. Patents 4,158,667 and 4,338,325 which discloses their utility as platelet aggregate inhibitors. 6a Carba prostacyclin carbacyclin and the 9 ss methyl derivative thereof, are disclosed in U.S. patents 4 238,414 and 4,420,632, respectively. Numerous other prostaglandins and their analogs are known. Thus,PGE1 is disclosed in U.S. Patent 3,069,322 and PGE2 is disclosed inU.S. patent 3,598,858. PGE2 esters are disclosed in U.S. patents 3,795,697 and 3,691,216. 20 Isopropylidene compounds are disclosed in Japanese Kokai 77 97946. Other prostaglandin analogs are disclosed in U.S. patents 3,069,322 3,598,858 3,636,120 3,639,463 3,691,216 3,706,789 3,725,454 3,726,909 3,728,382 3,759,978 3,776,938 3,776,939 3,795,697 3,8011,879 3,804,889 3,804,890 3,812,172 3,812,179 3.813,433 3.836,578 3.839,409 3.849,487 3.852,337 3,855,270 3,880,912 3,888,916 3,890,372 3,894,062 3,929,861 3,929,862 3,959,319 3,962,293 3,968,140 3,969,376 3,969,377 3,969,380 3,974,189 3,974,195 3,987,084 3,998,867 3,998,869 4,005,133 4,017,535 4,032,576 4,057,564 4,060,534 4,067,891 4,069,386 4,081,471 4.082,783 4,084,063 4,098,805 4,103,098 4,119,666 4,128,577 11,130,5811 11,130,720 4,130,721 4,139,564 4,158,667 4,171,460 4,176,236 4,197,257 4,205,178 4,220,796 3,903,131 3,954,741 11,187,381 3,972,917 4,052,512 3,823,180 4,107,191 4,147,879 and 4,165,436. Reversal by P 1 of the increase of microvascular permeability in sheep has been observed. Staub, N.C., Pulmonary Edema PhysiologicApproaches to Managment , Chest, Vol. 74, pp. 559 64 Nov. 1978 .Increased lung microvascular permeability has been associated with respiratory failure in endotoxin induced lung injury in sheep. Smith,Michael E. et al, Prostaglandin E1 and Prostacyclin Infusion DecreaseLung Injury11, Journal of Surgical Research Vol. 32 3 , 283 288, March 1982 . It has also been reported that many consider endotoxin induced lung injury to be the same as that seen clinically in sepsis. It has been stated that lung and systemic injury associated with endotoxin infusion has been decreased by the infusion of PGE1 and PGI2. Role of Prostacyclins in Acute Pulmonary Microvascular Injury , Demling, R.H., Annals New York Academy or Science, Vol. 3811, pp. 517 311 1982 .All of the reported studies, prior to this invention, relating to the use or POE1 or PGI2 to reduce microvascular permeability involve the treatment of animals in endotoxin induced lung injury. In most of the studies endotoxin induced lung injury was induced in sheep by in3ecting them with E. coli endotoxin and P1 and PGI2 were infused at rates of over 100 ng kg min and over 10 ngXkgXmin., respectively.See Demling et al, The Effect of Prostacyclin Infusion on EndotoxinInduced Lung Injury , Surgery, Vol. 89, No. 2, pp. 257 263 Feb. 1981 .Ogletree, M. L. et al, PGE1 Reduces Lung Transvascular FiltrationDuring Endotoxin Induced High Permeability in Sheep , Clinical Research,Vol. 27, No. 2, p. 402A, April 1979. Demling, et al, The Effect ofProstacyclin Infusion on Endotoxin Induced Lung Injury , Surgery,St. Louis, Vol. 89, No. 2, pp. 257 263 Feb. 1981 . Raflo, G.T. et al, Mechanism of the Protective Erfects of Prostaglandin El and F2a in Canine Endotoxin Shock , European Journal of Pharmacoiogy, 24, pp. 86 95 1973 . The survival rate of beagles suffering from hemorr hagic shock was improved by infusion with PGE1.Machiedo et al, nCom parison of Corticosteroids and Prostaglandins in Treatment of HemorrhagicShock , Annals of Surgery, Vol. 190, No 6, pp. 735 39, Dec. 1979 . PGI2 has been reported experimentally to be beneficial in increasing the survival rate after trauma. See, e.g., Lefer et al, BeneficialActions of Prostaglandins in Traumatic Shock , Prostaglandins 17 761 7, 1979. Breen et al, The Effects of P1 and Ibuprofen on Endotoxin InducedPulmonary Dysfunction A Biochemical and Electron Microscope Study ,Circ. Shock, 9, 2 , 197 1982 H.B. Hechtman, et al, The Management of Cardiorespiratory Failure in Surgical Patientsn, Advances in Surgery,Ed LD McLean, Vol. 15 1981 , pp. 123 156 and Lefer, Role of Prostaglandins and Thromboxanes in Shock States, Handbook of Shock andTrauma, Vol. I Basic Science New York 1983 . P.L. Appel and W.C. Shoemaker, in an abstract in the SymposiumSyllabus for the Critical Care Medicine 21st Annual Symposium March 3 6, 1983 and in Hemodynamic and Oxygen Transport Effects of Prostaglandin E1 in Patients with Adult Respiratory Distress Syndrome, CriticalCare Medicine, Vol. 12, No. 6, pp. 528 529, 1984, described the administration of PGE1 to 5 patients with severe postoperative ARDS. While it is reported that the lung function of each patient improved, it is also noted that three patients died of associated problems, including vital organ failure. According to the present invention, a PGE like prostaglandin is used to prepare a medicament for use especially human surgical or therapeutic treatment in treating or preventing ARDS, in treating or preventing multiple organ failure in a human having or prone to ARDS or organ failure, or in treating or preventing any one or combination of shock, trauma and sepsis. The medicament may be known per se. It may comprise the active ingredient and a pharmaceutically acceptable carrier or excipient. The medicament or pharmaceutical composition may be provided in a container. It may be in unit dosage form, e.g. a discrete solid or encapsulated liquid form. The amount of the active ingredient, the PGE like prostaglandin, in use or in a dosage unit should be sufficient for the given purpose, e.g. to be effective in the given use for at least 7 days. The PGE like prostaglandin may have the formulaEMI7.1 wherein N1 is 1 COOR1, wherein R1 is a hydrogen, b C1 C12 alkyl, c C1 C1O cycloalkyl, d c6 C16 aralkyl, e phenyl, optionally substituted by one, 2 or 3 substituents independently selected from chloro and C1 C3 alkyl, f phenyl substituted in the para position by i NH CO R25, ii CO R26, iii O CO R54 or iv CH N NH CO NH2 wherein R25 is methyl, phenyl, acetamidophenyl, benzamidophenyl, or NH2 R26 is methyl, phenyl, NH2, or methoxy and R511 is phenyl or acetamidophenyl inclusive, or g a pharmacologically acceptable cation 2 CH2OH, 3 COL4, wherein L4 is a amino of the formula NR51R521 wherein R51 and R52 are i hydrogen ii C1 C12 alkyl, iii C3 C10 cycloalkyl, iv C7 C12 aralkyl, v phenyl, optionally substituted with one, 2 or 3 chloro, C1 C3 alkyl, hydroxy, carboxy, C2 Cs alkoxycarbonyl, or nitro, vi C2 C5 carboxyalkyl, vii C2 C5 carbamoylalkyl, viii C2 C5 cyanoalkyl, ix C3 C6 acetylakyl, x C7 C11 benzoalkyl, optionally substituted by one, 2 or 3 chloro, C1 c3 alkyl, hydroxy, C1 C3 alkoxy, carboxy, C2 C5 alkoxycarbonyl, or nitro, xi pyridyl, optionally substituted by one, 2 or 3 chloro, C1 C3 alkyl, or C1 C3 alkoxy, xii C6 Cg pyridylalkyl optionally substituted by one, 2 or 3 chloro, C1 C3 alkyl, xiii C1 C4 hydroxyalkyl, xiv CCi C4 dihydroxyalkyl, xv C1 C4 trihydroxyalkyl, with the further proviso that not more than one of R51 and R52 is other than hydrogen or alkyl, b cycloamino selected from the group consisting of pyrrolidino, piperidino, morpholino, piperazino, hexa methyleneimino, pyrrolino, or 3,4 didehydropiperidinyl optionally substituted by one or 2 C1 C12 alkyl of one to 12 carbon atoms, inclusive, c carbonylamino of the formula NR53COR51, wherein R53 is hydrogen or C1 C4 alkyl and R51 is other than hydrogen, but otherwise as defined above, d sulfonylamino of the formula NR53S02R51, wherein R51 and R53 are as defined in c , e CH2NL2L3, wherein L2 and L3 are hydrogen or C1 C4 alkyl, being the same or different, or the pharmacologi cally acceptable acid addition salts thereof when N1 is CH2NL2L3, r C02R1, g CH20H, h CONR5R6, i cH2 NR5R6, or j CONHS02CH3 wherein M1 is cis or trans CH CH CH2 m , CH2 n , CH2 n 1 CF2 , CO CH2 3 CH2 , trans CH2 m CH CH CH CH CH2 m 1 CF2 , or CO CH2 3 CF2 wherein L1 is a OH B H, CH2, or oxo wherein R8 is hydrogen, hydroxy, or methyl wherein E1 is trans CH CH, CH2 CH2 , or C C wherein Q1 is alpha OH ss R2, alpha R2 ss OH, or oxo wherein A1 is alpha OH ss CH3, alpha CH3 ss H alpha H, alpha F ss F orCH3 wherein R7 is 1 CH2 p CH3, 2 cis CH CH CH2 CH3, 3 CH2 2 C CH, 4 CH2 3 CH C CH3 2, or 5 C R3R4 CH2 g CH2R14 wherein R2 is hydrogen or methyl wherein R3 and R4 are the same or different and are hydrogen or methyl wherein R5 and R6 are the same or different and are hydrogen, methyl, or ethyl wherein R14 is hydrogen or C1 C4 alkyl wherein gis an integer of from one to 4, inclusive wherein m is an integer of from 3 to 5, inclusive wherein n is an integer of from 5 to 7, inclusive and wherein p is an integer from one to 6, inclusive or the pharmacologically acceptable salts thereof when N1 is CONR53SO2R51. With regard to the divalent substituents described above e.g., L1, Q1 and A1 , these divalent radicals are defined as alpha Ri ss Rj, wherein Ri represents the substituent of the divalent moiety in the alpha configuration with respect to the plane of the C 8 to C 12 cyclopentane ring and Rj represents the substituent of the divalent moiety in the beta configuration with respect to the plane of the ring. Accordingly, when L1 is defined as alpha OH ss OH, the hydroxy of the L1 moiety is in the alpha configuration and the hydrogen substituent is in the beta configuration. The carbon atom content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maxiumum number of carbon aoms in the moiety, i.e., the prefix Ct C indicates a moiety of the integer i to the integer j carbon atoms, inclusive.Thus Cl C3 alkyl refers to alkyl of one to 3 carbon atoms, inclusive, or methyl, ethyl, propyl, and isopropyl. When Q1 contains a methyl substituent the compounds are all namedas 15 methyl compounds. Further, when the E1 moiety contains an hydroxyl in the beta configuration, such compounds are additionally named as .1 5 epi compounds. The prostaglandin compounds herein which contain CH2 2 , or C C as the E1 moiety, are accordingly referred to as 13,14 dihydro , or 13,1A didehydron compounds, respectively. When R7 is straight chained CH2 pCH3 wherein p is as defined above, the compounds so described are named as 19,20 dinor , 20nor , 20 methyl or 20 ethyl compounds when p is one, 2, 4, or 5, respectively. When R7 is branched chain C R3R4 CH2 g CH2RIII, then the compounds so described are 17 , 18 , 19 , or 20 alkyl or 17,17 , 17,18 , 17,19 , 17,20 , 18,18 , 18,19 , 18,20 , 19,19 , or 19,20 dialkyl compounds when g is 4 or 5 and the unbranched portion of the chain is at least n butyl, e.g., 17,20 dimethyl compounds are descibed when g is 5 1 methylpentyl . When R7 is cis CH CH CH2CH3, the compounds so described are named as cis 17,18 didehydro , compounds, When R7 is CH2 3 cH C CH3 2, the compounds so described are named as 20 isopropylidene compounds. When N1 is COL4, the compounds herein are named as amides. Further, when N1 is COOR1, the compounds herein are named as prostaglandin esters and salts. Examples of amides herein i.e., N1 is COL4 include the following 1 Amides within the scope of alkylamino groups of the formula NR51R52 are methylamide, ethylamide, n propylamide, n butylamide, n pentylamide, n hexylamide, n heptylamide, n octylamide, n nonylamide, n decylamide, n undecylamide, and n dodecylamide, and isomeric forms thereof. Further examples are dimethylamide, diethylamide, di npropylamide, di n butylamide, methyl ethylamide, methylpropylamide, methylbutylamide, ethylpropylamide, ethylbutylamide, and propylbutylamide.Amides within the scope of cycloalkylamino are cyclopropylamide cyclobutylamide, cyclopentylamide, 2,3 dimethylcyclopentylamide, 2, 2 dimethylcyclopentylamide, 2 methylcyclopentylamide, 3 tertbutylcyclopentyl amid, cyclohexylami de, tert butylcyclohexyl ami de, 3 isopropylcyclohexylamide, 2, 2 dimethylcyclohexvlami de, cycloheptylamide, cyclooctylamide, cyclononylamide, cyclodecylamide, N methyl Ncyclobutylamide, N methyl N cyclopentylamide, N methyl N cyclohexylamide, N ethyl N cyclopent yl ami de, and N ethyl N cyclohexylamide.Amides within the scope of aralkylamino are benzylamide, 2 phenylethylamide, and N methyl N benzyl amide. Amides within the scope of substituted phenylamide are p chloroanilide, m chloroanilide, 2,4 dichioroanilide, 2,1I,6 trichloroanilide, m nitroanilide, p nitroanilide, p methoxyanilide, 3,4 dimethoxyanilide, 3,11,5 trimethoxy anilide, phydroxymethylanili de, p methylanilide, m methylanilide, p ethylanilide, t butylanilide, p carboxyanilide, p methoxycarbonyl anilide, p carboxyanilide and o hydroxyanilide. Amides within the scope of carboxyalkylamino are carboxyethylamide, carboxypropylamide and carboxymethylamide, carboxybutylamide. Amides within the scope of carbamoylalkylamino are carbamoylmethylamide, carbamoylethylamide, carbamoylpropylamide, and carbamoylbutylamide. Amides within the scope of cyanoalkylamino are cyanomethylamide, cyanoethylamide, cyano propylamide, and cyanobutylamide. Amides within the scope of acetylalkylamino are acetylmethylamide, acetylethylamide, acetylpropylamide, and acetylbutylamide. Amides within the scope of benzoylalkylamino are benzoylmethylamide, benzoylethylamide, benzoylpropylamide, and benzoylbutylamide.Amides within the scope of substituted benzoylalkylamino are p chloroben zoylmethyl ami de m chlorobenzoylmethylamide, 2,4 dichlorobenzoylmethylamide, 2,4,6 trichlorobenzoylmethylamide, m nitrobenzoylmethylamide, p nitrobenzoylmethylamide, p methoxybenzoylmethylamide, 2,4 dimethoxybenzoylmethylamide, 3,4,5 trimethoxybenzoylmethylamide, p hydroxymethylbenzoylmethylamide, p methylbenzoylmethylamide, m methylben zoylmethyl ami de , pethylbenzoylmethyl ami de , t butylbenzoylmethylamide, p carboxybenzyolmethylamide, m methoxycarbonylbenzoylmethyl amide, ccarboxybenzoylmethylamide, o hydroxybenzoylmethylamide, p chlorobenzyolmethylamide, m chlorobenzyolmethylamide, 2,4 dichlorobenzyolethyl, amide, 2,4,6 trichlorobenzyolethylamide, m nitrobenzyolethylamide, p nitrobenzyolethylamide, p methoxybenzyolethylamide, p methoxybenzyolethylamide, 2,4 dimethoxybenzyolethylamide, 3,4,5 trimethoxybenzyolethylami de, p hydr oxymet hyl benzoyl ethyl ami de, p methylbenzoylethylamide, m methylbenzyolethylamide, p ethylbenzyolethylamide, t butylbenzyolethylami de, p carboxybenzoyl ethyl ami de, m methoxycarbonylbenzoylethylami de , o carboxybenzoylethlam de , o hydroxybenzoylethylamf de , p chlorobenzoyl propylamide, m chlorobenzyolpropylamide, 2,4 dichlorobenzyolpropylamide, 2,4,6 trichlorobenzyolpropylamide, m nitrobenzyolpropylamide, p nitrobenzoylpropylamide, p methoxybenzoylpropylami de, 2,4 dimethoxybenzoyl propylamide, 3,4,5 trimethoxybenzyolpropylamide, p hydroxymethylbenzyol propylamide, p methylbenzyolpropylamide, m methylbenzyolpropylamide, p ethylbenzoylpropylami de, t butylbenzoylpropylami de, p carboxybenzoyl propylamide, m methoxycarbonylbenzyolpropylamide, o carboxybenzyolpropyl amide, o hydroxybenzoylpropylamide, p chlorobenzoylbutylamide, mrchloro benzoylbutylamide, 2,4 dihclorobenzyolbutylamide, 2,4,6 trichlorobenzyol butylamide, m nitrobenzyolbutylamide, p nitrobenzyolbutylamide, p methoxy benzoylbutylamide, 2,4 dimethoxybenzyolbutyl amide, 3,4,5 trimethoxybenzo ylbutylamide, p hydroxybenzoylbutyl amide, p methylbenzoylbutylamide, m methylbenzoylbutylamide, p ethy√∂ benzoylbutylamide, m methylbenzoyl butylami de, p ethylbenzoylbutyl amide, t butylbenzoylbutylamide, p car boxybenzoylbutylamide , m methoxycarbonylbenzoylbutylamide, o carboxy benzoylbutylamide, o hydroxybenzoylmethylamide. Amides within the scope of pyridylamino are o pyridylamide, ss pyridylamide, and Y pyridylamide.Amides within the scope of substituted pyridylamino are 4 meth yl alpha pyridylamide, 4 methyl ss pyridylamide, 4 chloro pyridylamide, and g chloro B pyridyl ami de. Amides within the scope of pyridylalkylamino are a pyridylmethylamide, ss pyridylmethylamide, Y pyridylmethylamide, alpha pyridylethylamide ss pyridylethylamide, gamma pyridylethylamide, alpha pyridyl propylamide, B pyridylpropylamide, Y pyridylpropylamide, a pyridylbutylamide, ss pyridylbutylamide, and gamma pyridylbutylamide. Amides within the scope of substituted pyridylalkylamido are 4 methyl o pyridylmethyl amide, 4 methyl ss pyridylmethylamide, 4 chloro alpha pyridylmethylamide, 4 chl w,o B pyr I dylmethyl ami de , 4 methyl a pyr i dyl propyl ami de , 4 meth yl ss pyridylpropylamide, 4 chloro alpha pyridylpropylamide, 4 chloro ss pyrid ylpropylamide, 4 methyl alpha pyridylbutylamide, 4 methyl ss pyridylbutylamide, 4 chloro alpha pyridylbutylamide, 4 chloro ss pyridylbutylamide.Amides within the scope of hydroxyalkylamino are hydroxymethylamide, ss hydroxy ethylamide f3 hydroxypropylami de, gamma hydroxypropylamide, 1 hydroxy methyl ethylamide, 1 hydroxymethyl propylamide, 2 hydroxymethyl propylamide, and alpha , alpha , dimethyl hydroxyethylamide. Amides within the scope of dihydroxyalkylamino are dihydroxymethylamide, ss, gamma dihydroxypropylamide, 1 hydroxymethyl 2 hydroxymethylamide, ss, gamma dihydroxybutylamide, ss, di hydroxybutyl amide, Y, 6 dihydroxybutylamide, and 1, 1 bis hydroxymethyl ethylamide.Amides within the scope of trihydroxyalkylamino are tris hydroxy methyl methyl ami de and 1 , 3 di hydroxy 2 hydroxymethylpropylami de. 2 Amides within the scope of cycloamino groups described above are pyrrolidylamide, piperidylamide, morpholinylamide, hexamethylene iminylamide, piperazinylamide, pyrrolinylamide, and 3,11 didehydropiper idinylamide. 3 Amides within the scope of carbonylamino of the formula NR53COR51 are methylcarbonylamide, ethylcarbonylamide, phenylcarbonylamide, and benzylcarbonylamide. 1 Amides within the scope of sulfonylamino of the formula NR53S02R51 are methylsulfonyl ami de, ethylsufonyl ami de, phenylsulfonylamide, p tolylsulfonylamide, benzylsulfonylamide. Examples of alkyl of one to 12 carbon atoms, inclusive, are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, isomeric forms thereof. Examples of C3 C10 cycloalkyl which includes alkyl substituted cycloalkyl, are cyclopropyl, 2 methylcyclopropyl, 2, 2 dimethylcyclopropyl 2,3 diethylcyclopropyl, 2 butylcyclopropyl, cyclobutyl, 2 methylcyclobutyl, 3 prppylcyclobutyl, 2,3,4 triethylcyclobutyl, cyclopentyl, 2,2 dimethylcyclopentyl, 2 pentylcyclopentyl, .3 tert butylcyclopentyl, cyclohexyl, O tert butylcyclohexyl, 3 isopropylcyclohexyl, 2,2 dimethylcyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl. Examples of C7 C1 2 aralkyl are benzyl, 2 phenylethyl, 1 phenylethyl, 2 phenylpropyl, 4 phenylbutyl, 3 phenylbutyl, 2 1 naphthylethyl , and 1 2 naphthylmethyl . Examples of phenyl substituted by one to 3 chloro or alkyl of one to ZI carbon atoms, inclusive, are p chlorophenyl, m chlorophenyl, 2,4 dichlorophenyl, 2,4,6 trichlorophenyl, p tolyl, m tolyl, o tolyl, p ethylphenyl, p tert butylphenyl, 2, 5 diniethylphenyl, 4 chloro 2 methylphenyl, and 2,4 dichloro 3 methylphenyl. Examples of Cs C7 cycloalkyl optionally substituted by C1 C4 alkyl are cyclobutyl, 1 propylcyclobutyl, 1 butylcyclobutyl, 1 pentylcyclobutyl, 2 methylcyclobutyl, 2 propylcyclobutyl, 3 ethylcyclobutyl, 3 propylcyclo butyl, 2,3,4 triethylcyclobutyl, cyclopentyl, 2,2 dimethylcyclopentyl, 3 ethylcyclopentyl, 3 propylcyclopentyl, 3 butylcyclopentyl, 3 tert butylcyclopentyl, 1 methyl 3 propylcyclopentyl, 2 methyl 3 propylcyclopentyl, 2 methyl 4 propylcyclopentyl, cyclohexyl, 3 ethylcyclohexyl, 3 isopropylcyclohexyl, 4 methylcyclohexyl, 4 ethylcyclohexyl, 4 cyclopropylcyclohexyl, 4 butylcyclohexyl, 1i tert butylcyclohexyl, 2, 6 dimethylcyclohexyl, 2, 2 dimethylcyclohexyl, 2,6 dimethyl 4 propylcyclohexyl, and cycloheptyl. Pharmacologically acceptable cations within the scope of R1 include the pharmacologically acceptable metal cations, ammonium, amine cations, or quaternary ammonium cations. Especially preferred metal cations are those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminum, zinc, and iron are within the scope of this invention. Pharmacologically acceptable amine cations are those derived from primary, secondary, or tertiary amines. Examples of suitable amines are methylamine, dimethylamine, trimethylamine, ethylamine, dibutylamine, triisopropylamine, N methylhexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, dicyclohexylamine, benzylamine, dibenzylamine, orphenylethylamine, ss phenylethylamine, ethylenediamine, diethylenetriamine, and the like aliphatic, cycloaliphatic, araliphatic amines containing up to and including about 18 carbon atoms, as well as heterocyclicamines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower alkyl derivatives thereof, e.g., 1 methylpiperidine, 4 ethylmorpholine, 1 isopropylpyrrolidine, 2 methylpyrrolidine, 1,4 dimethylpiperazine, 2 methylpi peridine, and the like, as well as amines containing water solubilizing or hydrophilic groups, e.g, mono , di , and triethanolamine, ethyldiethanolamine, N butylethanolamine, 2 amino 1 butanol, 2 amino 2 ethyl 1,3 propanediol, 2 amino 2 methyl 1 propanol, tris hydroxymethyl aminomethane, N phenyl ethanol amine, N p tert amylphenyl diethanolamine, glactamine, N methylglycamine, N methylglucosamine, ephedrine, phenylephrine, epinephrine, procaine, and the like. Further useful amine salts are the basic amino acid salts, e.g., lysine and arginine. Examples of suitable pharmacologically acceptable quaternary ammonium cations are tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, phenyltriethylammonium, and the like. In accordance with the manner and process of using the present invention, a PGE1 like prostaglandin in pharmaceutical dosage form is administered systemically to humans to treat or prevent ARDS or multiple organ failure as described herein. The terms shock , trauma , and sepsis are used in their ordinary accepted meaning in the art.Shock may be generally described as a condition of acute circulatory failure due to derangement of circulatory control or loss of circulating fluid. It is frequently marked by palor and clamminess of the skin, decreased blood pressure, feeble rapid pulse, decreased respiration, restlessness, anxiety, and sometimes unconsciousness. Trauma may be generally described as any wound or injury. This can be the result of surgery. Sepsis may be generally described as a serious bacterial infection with a concurrent, deleterious systemic response. The term ARDS is well defined. in the medical literature, as described above.It is caused by well known factors, for example those noted above and in Table I. All of these terms are well known to physicians of ordinary skill. By severe vital organ failure is meant a decrease in functioning of a vital organ gastrointestinal tract, brain, liver, kidney, lung, or heart to the extent that the chance of survivability is low.By humans having or prone to vital organ failure is meant a human experiencing or recently experiencing a catastrophic event such as trauma, sepsis, shock or other events placing one at risk for ARDS or vital organ failure such as those listed above and in Table 1.These persons are readily identified by a skilled physician, using, e.g., these factors and the clinical symptoms set forth above. By unit dose is meant a discrete quantity of a prostaglandin and a carrier useful for systemic administration in the method of this invention. Thus, an ideal unit dose would be one wherein one unit, or an integral amount thereof, contains the precise amount of prostaglandin for this purpose. These unit doses can be packaged in a variety of forms. The prostaglandin may be dissolved or suspended in the carrier, or the prostaglandin and the carrier may be combined just prior to administration. Accordingly, the prostaglandin in pharmaceutical dosage form is systemically administered, preferably intravenously, to the patient at a rate of about t to 100 ng kg min for PGEi like compounds of theFormula I and 0.1 to 10 ng kg min for PGI2 its salts, esters, amides, and stabilized analogs, respectively, for a period of about 2 14 days or until the patient extubated, or until the patient is no longer threatened by the organ failure. The preferred rate is 20 to 30 ng kg min and 2 to 5 ng kg min, respectively, over a period of about 7 days. PRE1, its alkyl esters and salts are well known, readily available compound and can be prepared by methods known in the art. U.S. Patent 3,069,322 discloses such methods. The essential material constituting a disclosure of how to prepare PGE1, its lower alkyl esters and salts are incorporated by reference from U.S. Patent 3,069,322. Amides of POEl can be prepared by methods known in the art for converting carboxylic acid moieties to carboxylic acid amide moieties. Such methods are described, for example, in U.S. Patents 3,954,741 and 4,100,192 columns 10 and 11 . Both of these patents are expressly incorporated by reference herein. The other prostaglandins within the scope of this invention are known and can be synthesized by the methods described in the U.S.patents noted in the Information Disclosure statement above, which are expressly incorporated by reference herein. PGI2 and its pharmaceutical salts, esters and amides can be prepared by the methods disclosed in U.S. Patents 4,158,667 and 4,338,325. Stabilized analogs thereof are described in U.S. Patents 4,238,414 and 4,420,632. The essential material constituting a disclosure of how to prepare prostacyclin, its pharmaceutical salts, and stabilized analogs are incorporated by reference from these U.S. Patents. In accomplishing the purposes of this invention those compounds which are useful are those prostaglandins and prostaglandin derivatives which are at least 1S as potent as PGE1 in preventing and or ameliorating the deleterious consequences of trauma, sepsis, shock or other traumatic events listed in Table 1 under the conditions of the Examples. These compounds are referred to herein as PGE1 like compounds because of their similar biological activity. Examples of such compounds includePGI2, and salts, esters, amides and stabilized analogs thereof including carbacyclin and 9ss methyl carbacyclin , and those prostaglandins of the Formula I described above, particularly PGE1 15S 15 methyl PGE1 15R 15 methyl PGE1 16, 1 6 dimethyl PGE1 2 decarboxy 2 hydroxymethyl PGE1 PGE2 1 5 keto PGE2 16, 1 6 dimethyl PGE2 17S,20 dimethyl 6 oxo PGE1, methyl ester 17S,20 dimethyl trans delta 2 PGE1 PGE2, N methanesulfonylamide 9 deoxo 9 methylene 16,16 dimethyl PGE2 155 15 methyl P GE2 1 5R 1 5 methyl P GE2 11 deoxy 16,16 dimethyl PGE2 11 deoxy 11 alpha 16,16 trimethyl PGE2 6 oxo 11 deoxy 11 alpha 16,16 trimethyl PGE2 6 oxo PGE2 6 oxo PGE1 11 deoxy 15 methyl PGE1 PGE3 16, 16 difluoro PGE2 and 20 isopropylidene PGE1 as well as the alkyl esters, pharmacologically acceptable salts and derivatives thereof. These compounds may also be in stabilized forms including clathrates see, e.g., U.S. Patent 4,254,736 , triacetin see U.S. Patent 3,966,962 or triacetin ethanol see U.S.Patent 11,301,175 formulations, triacetin silicon dioxide gels see copending application S.N. 613,006, filed 21 May 19811 , and the like. These patents are incorporated by reference herein. PGE1 is the most preferred compound of this invention. Pharmaceutical dosage forms of PGE1 like compounds here for intravenous infusions can be formulated by known conventional methods.Other dosage forms of these compounds are also well known. PGE1, also known as alprostadil, is the active ingredient of Prostin VR Pediatric, which is sold by The Upjohn Company to aid in the maintenance of patency of the ductus arteriosis in neonates.See, physicians Desk Reference, p. 2043 38th Ed. 1984 . This sterile solution of P POE1 is most preferred for use in the method of the instant invention. A similar formulation can be used for other prostaglandins. For the treatment or prevention of ARDS or organ failure the PGEi like prostaglandin in a pharmaceutical dosage form is preferably administered through a central venous catheter or through the right atrial port of a Swan Ganz catheter, and the dosage is increased until a dose of 30 ng kg min is reached. The dosage is calculated on the basis of the patient s pre illness weight. A preferred method of administration is to begin with an infusion rate of 5 ng kglmin and to increase the dose by 5 ng kg min every 30 minutes until a rate of 30 ng kg min is obtained. The prostaglandin is given for a total of seven days, until the patient is extubated, or as long as the patient is threatened by organ failure.The infusion rate of 1 to 100 ng kg min is maintained as long as the mean systemic arterial pressure does not decrease more than twenty 20 percent from baseline levels. If there is a decrease of more than 20 in the arterial pressure, the infusion rate is decreased until levels within 20S of baseline levels are reached again. Discontinuing the drug preferably proceeds by decreasing the dosage 10 ng kg min per hour. Equivalent dosages for other PGEi like prostaglandins are also employed, based on the compound s potency as compared to PGE1. The identical procedure is utilized for the treatment or prevention of ARDS and or multiple organ failure with PGI2 and salts, esters, amides, and stabilized analogs thereof, except that the dosage is 0.1 to 10 ng kg min., preferably 2 to 5 ng kg min. The intravenous route is preferred for PGEl like prostaglandins including PGI2, its salts, esters, and amides . However, other systemic and non systemic routes of administration e.g., oral, enteral, rectal, parenteral including via implanted devices, intra arterial, cutaneous as via patches may also be employed as long as the dosage used achieves the same blood level of drug or equivalent effect as the intravenous route. A convenient route may be into the right atrium through the right atrial port of a Swan Ganz catheter, if such a catheter is in place. The following Examples are illustrative of the uses of this invention, but are not to be construed as limiting.Example 1 Treating Severe Lung Failure with PGE1 An intravenous solution was prepared by mixing one 5 ml ampoule of Prostin VR Pediatric Sterile Solution containing 2.5 mg PGE1 active drug with one liter of Dsw or Normal Saline. Dosages of this solution or of a control solution containing only vehicle but no PGE1 were administered to 41 patients suffering from ARDS in a prospective randomlzed double blind placebo controlled study. PGE1 or the control solution was started at a dose of 5 ng kg mln and then increased 5 ng kg min every 30 minutes until a rate of 30 ng kg min was reached. This dosage was continued for 7 days or until the patient was extubated, whichever came sooner. The survival rate 30 days after discontinuing the infusion was as follows Treatment Number of Patients Survival Rate S PGE1 21 71.4 Control 20 35.0Example 2 treating Severe Organ Failure with P 1 Fifty patients with ARDS were randomized to receive POE1 30 ng kg min for 7 days or placebo equivalent volumes of saline and time in a double blind study. For entry, patients must have required mechanical ventilation with an inspired oxygen concentration of 40 or more and a positive end respiratory pressure of 5 cm of water or more.Most of the patients 70Z were septic. 17 out of 26 patients who had received P 1 survived 65 survival while only 7 out of 24 patients who had received placebo survived 29 survival . The relation between the bilirubin and creatinine levels and the mortality of the patients enrolled in this study is depicted inTable 2. As can be seen, there is a significantly higher survival rate for those patients who were treated with POE1 while their creatinine and bilirubin levels are in the normal range. Creatinine and bilirubin levels are indicative of kidney and liver function, respectively.The data thus indicate that P 1 prevents severe kidney and liver damage, and greatly decreases the risk of death, for patients highly susceptible to kidney failure, liver failure, and or death as a result of trauma, sepsis, shock, and similar catastrophic events. Example 3 Preventing Organ Failure with P 1 A patient with peritonitis diagnosed at surgery has a significant risk of developing multiple organ failure 20 30 . The patient has an intravenous line placed so that its tip resides in the subelavian vein. A solution of PGE1 in normal saline 2.5 mg in 1 1 saline is infused at the rate of 5 ng kg min. The dose is increased at the rate of 5 ng kg min every 30 minutes until a maximum infusion rate of 30 ng kg min is achieved. This dosage is continued for 7 days to prevent the development of severe organ failure, including ARDS.During this period the peritonitis is brought under control surgically as needed and with antibiotic therapy. Example 4 Preventing Organ Failure with PGE2 A patient is involved in a motor car accident and receives severe damage to the abdominal region with massive internal bleeding. During the period prior to shortly after surgical repair of the abdominal injuries a total of 8 units of blood were required to maintain an adequate blood volume. This subjects the patient to significant risk for the development of organ failure. An intravenous line is established in the subclavian vein and PGE2 in normal saline 2.5 mg in 1 1 saline is infused at the rate of 5 ng kg min. This dose is increased at the rate of 5 ng kg min every 30 minutes to a maximum of 30 ng kg min.This dosage is continued for 5 days to prevent the development of vital organ dysfunction.Example 5 Preventing Organ Failure with PGI2 A patient is admitted to the intensive care unit with labored breathing following surgery. During induction of anesthesea, the patient aspirates stomach contents into the lungs which results in pulmonary insufficiency. A venous line is established and a solution of prostacyclin PGI2 is infused at the rate of 2.5 ng kg min. This infusion rate is maintained for 7 days to prevent the development of vital organ liver, kidney, lung, heart failure. The patient is retained for an additional 2 days in the intensive care unit ICU .Example 6 Preventing Organ Failure with PGE1 A patient is admitted to the hospital emergency room following a fall of 8 stories from a building under construction. He has six fractured ribs, a fractured tibia and multiple contusions. The broken tibia is set and the patient is held for observation. During the fifth day his blood bilirubin levels, which had been rising, are at 6 mg dl and his creatinine levels are 2.2 mg dl. Infusion of a solution of POE1 in dextrose is started into the subclavian vein at the rate of 5 ng kg min and increased over a period of 2 hours to 30 ng kg min.This dosage is continued for 7 days to prevent further organ damage from occurring. TABLE 1 CONDITIONS ASSOCIATED WITH ARDSShock Drug Overdose Hemorrhagic Heroin Hypovolemic Hethadone Traumatic . Barbiturates Septic Ethchlorvynol Cardiogenic Cadiac Compressive Anaphylactic Neurogeni c ToxicTrauma Disseminated Intravascular Coagulation Fat Emboli Lung Contusion Near Drowning Nonthoracic Trauma Fresh or Salt WaterInfection Miscellaneous Viral Pneumonia Pancreatitis Bacterial Pneumonia Uremia Fungal Pneumonia Postcardiopulmonary Bypass PostcardioversionInhalation of Toxic Gases Air or Amniotic Fluid Emboli Oxygen FI02 0.5 Multiple Transfusions Smoke Combustion Products Nitrous Oxide Industrial SolventsAspiration of Gastric Contents Especially with a pH 2.5 TABLE 2 Percent Mortality N PGE Placebo Normal creatinine 18 17 65 17 Normal bilirubin 15 13 44 9 Normal creatinine.and bilirubin 9 11 44 9 Abnormal creatinine 67 9 83 6 Abnormal bilirubin 58 12 86 t4 Abnormal creatinine and bilirubin 71 7 83 6 Abnormal 1.5 mg dlN number of patients in study